ProQR Therapeutics (NASDAQ:PRQR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a strong sell rating to a hold rating in a research report report published on Saturday.

PRQR has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday, January 22nd. Oppenheimer started coverage on ProQR Therapeutics in a research report on Thursday, March 12th. They issued an “outperform” rating and a $9.00 price target on the stock. Finally, Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research note on Friday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, ProQR Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $6.80.

ProQR Therapeutics Trading Down 3.3%

Shares of NASDAQ PRQR opened at $1.76 on Friday. The business’s 50 day moving average is $1.64 and its 200-day moving average is $2.06. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $3.10. The firm has a market cap of $185.43 million, a P/E ratio of -3.83 and a beta of 0.21.

ProQR Therapeutics (NASDAQ:PRQR) last posted its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). ProQR Therapeutics had a negative return on equity of 65.89% and a negative net margin of 255.83%.The firm had revenue of $5.50 million for the quarter, compared to analyst estimates of $6.12 million. Analysts forecast that ProQR Therapeutics will post -0.31 EPS for the current year.

Hedge Funds Weigh In On ProQR Therapeutics

Several large investors have recently modified their holdings of PRQR. Osaic Holdings Inc. lifted its holdings in shares of ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares during the period. Guggenheim Capital LLC bought a new stake in shares of ProQR Therapeutics in the fourth quarter worth $35,000. Moody Lynn & Lieberson LLC acquired a new stake in ProQR Therapeutics in the fourth quarter valued at $50,000. Invesco Ltd. bought a new position in ProQR Therapeutics during the 4th quarter worth $51,000. Finally, Fifth Third Bancorp bought a new position in ProQR Therapeutics during the 3rd quarter worth $64,000. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.